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Aims Patients with pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH) after defect
correction have a poor prognosis compared with other CHD-PAH patients. Therefore, it is important that these
patients are treated as early and effectively as possible. Evidence supporting the use of PAH therapies in patients with
corrected CHD-PAH from randomised controlled trials is limited. The purpose of these analyses was to characterise
the corrected CHD-PAH patients from the GRIPHON study and examine the response to selexipag.
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Methods
and results
Out of the 110 patients diagnosed with corrected CHD-PAH, 55 had atrial septal defects, 38 had ventricular septal
defects, 14 had persistent ducti arteriosus, and 3 had defects not further specified. Hazard ratios (HR) and 95%
confidence intervals (CI) for the primary composite endpoint were calculated using Cox proportional hazard models.
Compared with the non-CHD patients from GRIPHON, patients with corrected CHD-PAH were slightly younger,
with a greater proportion being treatment-naive and in World Health Organization functional class I/II. The rate
of the primary composite endpoint of morbidity/mortality was lower in patients with corrected CHD-PAH who
were treated with selexipag compared with those treated with placebo (HR 0.58; 95% CI 0.25, 1.37). The most
common adverse events were those known to be related to selexipag.
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Conclusions These post-hoc analyses of GRIPHON provide valuable information about a large population of patients with
corrected CHD-PAH, and suggest that selexipag may delay disease progression and was well-tolerated in patients
with corrected CHD-PAH.
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Introduction
Pulmonary arterial hypertension (PAH) associated with congenital
heart disease (CHD) (CHD-PAH) is one of the most frequent
aetiologies of PAH.1–6 Due to improvements in the diagnosis
and surgical treatment of paediatric CHD, the number of adults
living with CHD-PAH is growing.7 CHD-PAH characterised
by shunt lesions is a heterogeneous population consisting of
four subgroups: (i) Eisenmenger’s syndrome; (ii) PAH associated
with predominant systemic-to-pulmonary shunts; (iii) PAH with
small/coincidental defects; and (iv) PAH after defect correction
(corrected CHD-PAH).8 Patients with CHD-PAH are generally
perceived as having a better survival than patients with idio-
pathic PAH (IPAH).9 However, patients with corrected CHD-PAH
seem to have a poor prognosis compared with other types of
CHD-PAH,5,8,10 and are reported to have a survival comparable
to that of IPAH patients.5 Therefore, there is a need for early and
effective management of patients with corrected CHD-PAH.
Evidence supporting the use of PAH therapies in patients with
corrected CHD-PAH has recently started to emerge.10–12 Two
recent large PAH randomised controlled trials (RCTs) (SERAPHIN
and PATENT) enrolled 62 and 35 patients, respectively, with
corrected CHD-PAH; subgroup analyses revealed beneficial effects
of PAH therapy in these patients.11,12
The long-term, event-driven, randomised, placebo-controlled,
phase III GRIPHON trial, which evaluated the selective IP prosta-
cyclin receptor agonist selexipag, enrolled 110 patients with cor-
rected CHD-PAH. In the overall GRIPHON population, selexipag
reduced the risk of the primary composite outcome of morbid-
ity/mortality by 40% (P < 0.001) compared with placebo13; the
treatment effect was consistent in the corrected CHD-PAH sub-
group. The current analyses further examined the efficacy, safety
and tolerability of selexipag in this large population of patients with
corrected CHD-PAH enrolled in GRIPHON.
Methods
Study population
GRIPHONwas a global, double-blind, randomised, placebo-controlled,
event-driven, phase III trial (NCT01106014) described in detail
elsewhere.13 Patients (18–75 years) with a diagnosis of PAH confirmed
by right heart catheterisation and a 6-minute walk distance (6MWD)
of 50–450m at baseline were eligible.13 The study enrolled patients
with corrected CHD-PAH who had repaired (for ≥ 1 year) congenital
simple systemic-to-pulmonary shunts, and patients with IPAH or her-
itable PAH, or PAH associated with connective tissue disease, human
immunodeficiency virus infection or drug/toxin exposure.13 Patient
aetiology was specified by the investigator. Patients with corrected
CHD-PAH were enrolled at 56 sites in 26 countries. Eligible patients
were treatment-naive or receiving a phosphodiesterase-5 inhibitor,
an endothelin receptor antagonist, or both, at doses that were stable
for at least 3months prior to randomisation.13 All patients provided
written informed consent.13
Study design
Patients were randomised (1:1) to receive selexipag or placebo twice
daily (b.i.d.). During a 12-week titration period, study drug was initiated ..
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.. at 200𝜇g b.i.d. and titrated weekly in increments of 200𝜇g b.i.d.
to the highest tolerated dose. The maximum allowed dose was 1600𝜇g
b.i.d.13 At the end of the titration period, patients entered the main-
tenance phase. Dose increases were allowed at scheduled visits from
Week 26; dose reductions were allowed at any time.13 The individu-
alised maintenance dose (IMD) was the dose that the patient received
for the longest duration in the study. IMDs were categorised into
three pre-specified dose groups: low (200 and 400𝜇g b.i.d.), medium
(600, 800 and 1000𝜇g b.i.d.) or high (1200, 1400 and 1600𝜇g b.i.d.).13
The double-blind treatment period ended when the patient experi-
enced a primary endpoint event, prematurely discontinued study drug,
or when the study ended (for patients with no primary endpoint
event).13 The study ended when the pre-specified number of 331 pri-
mary endpoint events was reached.13 GRIPHON was conducted in
accordance with the Declaration of Helsinki and the protocol was
approved by local institutional review boards or independent ethics
committees.13
Outcome measures
The primary composite endpoint was the time from randomisation
to first morbidity/mortality event up to the end of double-blind
treatment. Morbidity events included disease progression, or wors-
ening of PAH that resulted in hospitalisation, initiation of parenteral
prostanoid therapy or long-term oxygen therapy, or need for lung
transplantation or balloon atrial septostomy.13 Disease progression
was defined as a decrease of≥15% in 6MWD from baseline (confirmed
by a second test on a different day), and worsening in World Health
Organization functional class (WHO FC) for patients in WHO FC II
or III at baseline or the need for additional PAH therapy for patients in
WHO FC III or IV at baseline.13 All primary endpoint events were adju-
dicated by a blinded independent committee.13 Secondary endpoints
included change in 6MWD from baseline to Week 26 and death from
any cause up to the end of the study.13 Exploratory endpoints included
the change in N-terminal pro-brain natriuretic peptide (NT-proBNP)
level from baseline to Week 26.13 Adverse events (AEs) and serious
adverse events (SAEs) were recorded throughout the study and up to
7 and 30 days, respectively, after the end of treatment.13
Statistical analyses
Exploratory post-hoc analyses were conducted on the subgroup
with corrected CHD-PAH from GRIPHON. Kaplan–Meier estimates
by treatment arm were calculated for the primary composite endpoint.
Cox proportional-hazard models were used to estimate hazard ratios
(HR) with 95% confidence intervals (CI).13 A non-parametric analysis
of covariance, with adjustment for the respective baseline value, was
used to analyse changes from baseline in 6MWD and NT-proBNP
levels. Values at Week 26 were imputed as 0m if the patient was
unable to walk, or as 10m (second lowest observed 6MWD value at
Week 26 irrespective of treatment) if the former rule did not apply.13
The analysis of NT-proBNP levels was performed on observed data
(40 placebo and 53 selexipag patients).13
Results
Patient characteristics
Of the 1156 patients enrolled in GRIPHON, 110 patients were
diagnosed with corrected CHD-PAH, including 55 (50%) patients
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics of patients with pulmonary arterial hypertension associated with congenital heart
disease after defect correctiona
Characteristic Corrected CHD-PAH population Non-CHD population
(n= 1046). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Placebo (n= 50) Selexipag (n= 60) Overall (n=110)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Female sex, n (%) 42 (84.0) 46 (76.7) 88 (80.0) 835 (79.8)
Age years, mean± SD 40.3±14.8 40.2±15.4 40.3± 15.1 48.9±15.2
Geographic region, n (%)
Asia 17 (34.0) 15 (25.0) 32 (29.1) 196 (18.7)
Eastern Europe 21 (42.0) 24 (40.0) 45 (40.9) 259 (24.8)
Latin America 4 (8.0) 8 (13.3) 12 (10.9) 98 (9.4)
North America 2 (4.0) 8 (13.3) 10 (9.1) 183 (17.5)
Western Europe/Australia 6 (12.0) 5 (8.3) 11 (10.0) 310 (29.6)
Time since diagnosis of PAHb, years, mean± SD 3.5± 5.5 3.6± 6.1 3.6± 5.8 2.3± 3.3
WHO FC, n (%)
I – 1 (1.7) 1 (0.9) 8 (0.8)
II 28 (56.0) 38 (63.3) 66 (60.0) 463 (44.3)
III 22 (44.0) 21 (35.0) 43 (39.1) 564 (53.9)
IV – – – 11 (1.1)
6MWD, m, mean± SD 358.7± 72.9 366.6± 71.4 363.0± 71.9 352.2± 80.8
Use of medications for PAH, n (%) 35 (70.0) 40 (66.7) 75 (68.2) 845 (80.8)
None 15 (30.0) 20 (33.3) 35 (31.8) 201 (19.2)
ERA 7 (14.0) 11 (18.3) 18 (16.4) 152 (14.5)
PDE-5i 18 (36.0) 19 (31.7) 37 (33.6) 337 (32.2)
ERA and PDE-5i 10 (20.0) 10 (16.7) 20 (18.2) 356 (34.0)
NT-proBNPc, ng/L, median (Q1, Q3) 471 (186, 1390) 286 (99, 752) 336 (124, 986.5) 593.5 (196, 1654)
6MWD, 6-minute walk distance; CHD, congenital heart disease; ERA, endothelin receptor antagonist; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary
arterial hypertension; PDE-5i, phosphodiesterase-5 inhibitor; SD, standard deviation; WHO FC, World Health Organization functional class.
aTesting of baseline characteristics showed there were (i) no significant differences (P > 0.05) between placebo and selexipag at baseline in the corrected CHD-PAH patients
with the exception of NT-proBNP (P < 0.05), and (ii) significant differences (P < 0.05) between the corrected CHD-PAH and non-CHD populations with the exception of
sex and 6MWD (P > 0.05) [comparisons to placebo were conducted using Fisher’s exact test (sex, geographic region, WHO FC and use of medications for PAH), unadjusted
analysis of variance (age and time since diagnosis of PAH) and Wilcoxon-Mann-Whitney test (6MWD and NT-proBNP)].
bConfirmed by right heart catheterisation.
cIncludes all patients with a baseline assessment: for the corrected CHD-PAH population, n= 49 for placebo and n= 59 for selexipag; for the overall non-CHD population,
n=1034.
with atrial septal defects, 38 (34%) with ventricular septal defects,
14 (13%) with persistent ducti arteriosus, and 3 (3%) with defects
not further specified. Of the 110 patients, 50 were randomised
to receive placebo and 60 to receive selexipag. Baseline charac-
teristics of corrected CHD-PAH patients were balanced between
treatment arms, with the exception of NT-proBNP level (median
of 471 ng/L for placebo vs. 286 ng/L for selexipag; Table 1). With
a mean (standard deviation) age of 40.3 (15.1) years, corrected
CHD-PAH patients were younger than patients in the non-CHD
population [mean age of 48.9 (15.2) years]. Furthermore, in com-
parison with the non-CHD population, a greater proportion of
patients with corrected CHD-PAH were in WHO FC I/II and
treatment-naive at baseline, with fewer corrected CHD-PAH
patients receiving combination therapy. There were also regional
differences between the corrected CHD-PAH group and the
non-CHD population.
Treatment exposure and dose
The median (range) duration of placebo and selexipag
administration was 78.6 (0.7–179.0) and 76.9 (2.3–164.9)
weeks, respectively, in corrected CHD-PAH patients. Within ..
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. the corrected CHD-PAH population, 36.7%, 28.3% and 35.0%
of selexipag-treated patients had their IMD in the low-, medium-
and high-dose groups, respectively (online supplementary
Table S1).
Efficacy outcomes
In the corrected CHD-PAH population, 13 (26%) patients in the
placebo arm and 9 (15%) patients in the selexipag arm experienced
a primary endpoint event (Table 2), as previously reported.13 The
rate of the primary composite endpoint of morbidity/mortality
was lower in patients treated with selexipag compared with those
treated with placebo (HR 0.58; 95% CI 0.25, 1.37) (Figure 1),
which is consistent with that in the overall GRIPHON population
(interaction P-value in the PAH aetiology subgroups 0.98).13 Among
patients with corrected CHD-PAH, hospitalisation for worsening
of PAH and disease progression accounted for the majority of
primary endpoint events (90.9%) (Table 2); this was also observed
in the overall population.13 By the study end, seven patients with
corrected CHD-PAH had died (5 in the placebo group and 2 in the
selexipag group) (Table 2).
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Events related to pulmonary arterial hypertension and death for patients with pulmonary arterial
hypertension associated with congenital heart disease after defect correction
Placebo
(n= 50)
Selexipag
(n= 60)
Overall
(n= 110)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Primary composite endpoint of morbidity/mortality up to the end of treatment
All events, n (%) 13 (26.0) 9 (15.0) 22 (20.0)
Hospitalisation for worsening of PAH 7 (14.0) 8 (13.3) 15 (13.6)
Disease progression 4 (8.0) 1 (1.7) 5 (4.5)
Death from any cause 2 (4.0) – 2 (1.8)
Initiation of parenteral prostanoid therapy or long-term O2 therapy for worsening PAH – – –
Need for lung transplantation or balloon atrial septostomy for worsening of PAH – – –
Secondary endpoint of all-cause death up to the end of the study
Death from any cause, n (%) 5 (10.0) 2 (3.3) 7 (6.4)
PAH, pulmonary arterial hypertension.
Figure 1 Effect of selexipag on the primary composite endpoint of morbidity/mortality in patients with pulmonary arterial hypertension
associated with congenital heart disease after defect correction.
At Week 26, in patients with corrected CHD-PAH, the 6MWD
increased by a median of 2m from baseline to Week 26 in the
placebo group and 11m in the selexipag group (treatment effect:
15m, 95% CI −7, 40) (Table 3). For NT-proBNP, there was a
treatment effect of −8 ng/L (95% CI −88, 69) for selexipag vs.
placebo (Table 3).
Safety and tolerability
In patients with corrected CHD-PAH, 4 (8.0%) placebo patients
and 5 (8.3%) selexipag patients discontinued their treatment pre-
maturely due to an AE (Table 4); 7.1% placebo and 14.3% selexipag
in the overall GRIPHON population13 prematurely discontinued ..
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.. their treatment due to an AE. The frequency of AEs reported in
the placebo (98.0%) and selexipag (95.0%) groups was compara-
ble. This is similar to that in the overall GRIPHON population
(96.9% in placebo and 98.3% in selexipag).13 The most common
AEs in the selexipag-treated group in corrected CHD-PAH patients
were headache, myalgia and diarrhoea. The proportion of patients
with corrected CHD-PAH who reported ≥1 SAE was similar in
the selexipag (30.0%) and placebo (32.0%) groups. No SAEs were
reported more frequently in the selexipag group compared with
the placebo group (with > 2% difference in frequency between the
selexipag and placebo groups). AEs associated with therapies that
target the prostacyclin pathway were more frequently reported
during the titration period than the maintenance period (Table 5).
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Table 3 Change in 6-minute walk distance and N-terminal pro-brain natriuretic peptide from baseline to Week 26 for
patients with pulmonary arterial hypertension associated with congenital heart disease after defect correction
Placebo
(n= 50)
Selexipag
(n= 60)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Median at
baseline
(Q1, Q3)
Median at
26weeks
(Q1, Q3)
Median
change
(Q1, Q3)
Median at
baseline
(Q1, Q3)
Median at
26weeks
(Q1, Q3)
Median
change
(Q1, Q3)
Treatment
effect
(CI)a
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6MWD, m 369 (320, 423) 357 (240, 412) 2 (−39, 37) 379 (333, 421) 387 (346, 431) 11 (−16, 40) 15 (−7, 40)
NT-proBNPb, ng/L 426 (151, 1280) 518 (171, 1065) −11 (−107, 81) 286 (98, 649) 236 (97, 684) −4 (−89, 52) −8 (−88, 69)
6MWD, 6-minute walk distance; CI, confidence interval; NT-proBNP, N-terminal pro-brain natriuretic peptide.
Values at Week 26 were imputed as 0m if the patient was unable to walk, or as 10m (second lowest observed 6MWD value at Week 26 irrespective of treatment) if the
former rule did not apply; 20% of patients in the placebo group, and 10% in the selexipag group had imputed values at Week 26.13 For NT-proBNP values, only patients with
a non-missing value at both baseline and at the Week 26 visit are included.
aPoint estimate for location shift as estimated by Hodges–Lehmann method (95% CI reported for 6MWD and NT-proBNP).
bThere were fewer patients (40 placebo and 53 selexipag) with NT-proBNP data.
Table 4 Most frequent adverse events in patients with
pulmonary arterial hypertension associated with
congenital heart disease after defect correction
Variable Placebo
(n= 50)
Selexipag
(n= 60)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Adverse events, n 225 411
Patients with ≥1 AE, n (%) 49 (98.0) 57 (95.0)
Patients with ≥1 SAE, n (%) 16 (32.0) 18 (30.0)
Patients with AE leading to
discontinuation of study drug, n (%)
4 (8.0) 5 (8.3)
AEsa, n (%)
Headache 19 (38.0) 40 (66.7)
Myalgia 5 (10.0) 19 (31.7)
Diarrhoea 2 (4.0) 21 (35.0)
Pain in jaw 2 (4.0) 18 (30.0)
Nausea 1 (2.0) 18 (30.0)
Worsening of PAH 11 (22.0) 7 (11.7)
Upper respiratory tract infection 9 (18.0) 8 (13.3)
Dyspnoea 7 (14.0) 6 (10.0)
Peripheral oedema 7 (14.0) 6 (10.0)
Fatigue 4 (8.0) 8 (13.3)
Arthralgia – 11 (18.3)
Dizziness 2 (4.0) 8 (13.3)
Flushing 2 (4.0) 8 (13.3)
Vomiting – 7 (11.7)
AE, adverse event; SAE, serious adverse event.
aAEs listed are those that occurred in more than 10% of the patients in any study
group during the double-blind period and up to 7 days after placebo or selexipag
was discontinued.
Discussion
GRIPHON included the largest population of patients with cor-
rected CHD-PAH evaluated in a RCT to date. In these patients,
the treatment effect of selexipag on the primary composite end-
point of morbidity/mortality was consistent with that in the over-
all population13 and selexipag was well tolerated. These results ..
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. contribute to the small but growing body of evidence that cor-
rected CHD-PAH patients benefit from PAH therapy.11,12,14–16
There were differences between corrected CHD-PAH
patients and the non-CHD population.13 Patients with corrected
CHD-PAH were younger, more likely to be in WHO FC I/II and
less likely to be on background therapy. The greater proportion of
patients in WHO FC I/II imply that corrected CHD-PAH patients
are less functionally impaired at enrolment than those with other
types of PAH. As the European Society of Cardiology guidelines
for the management of adult CHD suggest lifelong and regular
follow-up, even in the case of successful correction,17 it may be
possible that CHD patients who develop PAH are diagnosed at an
earlier stage of PAH than other types of PAH, therefore presenting
less physically impaired at enrolment. The lower proportion of
corrected CHD-PAH patients on background therapy may reflect
geographical differences between these patients and the overall
study population, as a higher proportion of patients with corrected
CHD were enrolled in regions where access to therapies may be
limited by lack of regulatory approval or reimbursement. It can
also be speculated that CHD patients who subsequently develop
PAH may be less likely to be treated if there is a perception among
clinicians that these patients have a less severe disease than other
forms of PAH.
Descriptive analysis of the primary endpoint Kaplan–Meier
curves showed that patients with corrected CHD-PAH displayed
slower disease progression than the overall study population.13
Although this may give the perception of a less severe disease in
this patient group, other analyses have shown corrected CHD-PAH
patients to have a similarly poor prognosis5 and similar haemody-
namic profile18,19 to IPAH patients when the shunt is closed. The
right heart loses its ability to decompress though a right-to-left
shunt and is prone to failure, similar to IPAH. Furthermore, data
from a long-term retrospective analysis of 192 CHD-PAH patients
indicate that corrected CHD-PAH patients had a worse outcome
than those with other forms of CHD-PAH.10 Possible reasons why
patients in our study had a better outcome than expected include
the exclusion of patients with complex defects, as morbidity and
mortality are reported to be high in this group of patients.20,21
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Table 5 Prostacyclin-associated adverse events reported in the study titration and maintenance periods for patients
with pulmonary arterial hypertension associated with congenital heart disease after defect correction
Titration period Maintenance period
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Placebo
(n= 50)
Selexipag
(n= 60)
Placeboa
(n= 46)
Selexipaga
(n= 59)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Exposure to double-blind treatment, weeks, median (range) 12.4 (0.7–12.4) 12.4 (2.3–12.4) 73.4 (2.9–166.6) 64.6 (1.9–152.4)
Patients with ≥1 prostacyclin-associated AE, n (%) 24 (48.0) 53 (88.3) 14 (30.4) 41 (69.5)
AE, n (%)
Headache 17 (34.0) 40 (66.7) 8 (17.4) 25 (42.4)
Diarrhoea 1 (2.0) 18 (30.0) 1 (2.2) 13 (22.0)
Myalgia 4 (8.0) 17 (28.3) 3 (6.5) 12 (20.3)
Pain in jaw 1 (2.0) 17 (28.3) 2 (4.3) 13 (22.0)
Nausea 1 (2.0) 15 (25.0) – 9 (15.3)
Arthralgia – 9 (15.0) – 8 (13.6)
Flushing 2 (4.0) 7 (11.7) 1 (2.2) 5 (8.5)
Pain in extremity 4 (8.0) 5 (8.3) 3 (6.5) 6 (10.2)
Vomiting – 5 (8.3) – 3 (5.1)
Dizziness 1 (2.0) 3 (5.0) 1 (2.2) 5 (8.5)
Temporomandibular joint syndrome – 2 (3.3) – 2 (3.4)
AE, adverse event.
A patient with multiple occurrences of an AE during one treatment period is counted only once in the AE category for that treatment and period.
aAmong the patients randomly assigned to each treatment arm, 4 in the placebo group and 1 in the selexipag group did not receive study treatment in the maintenance phase.
Furthermore, the length of time since defect correction is not
known but may have impacted on the rate of disease progres-
sion. In corrected CHD-PAH patients, the effect of selexipag on
the risk of the composite primary endpoint of morbidity/mortality
was comparable to that in the overall population. These results on
long-term outcomes add to those from SERAPHIN11 and provide
additional evidence for the use of PAH therapy in patients with
corrected CHD-PAH.
The effect of selexipag on the secondary endpoint of change
from baseline to Week 26 in 6MWD was similar between cor-
rected CHD-PAH patients and the overall study population,13
but lower than that in the post-hoc subgroup analysis of cor-
rected CHD-PAH patients treated with riociguat in PATENT.12 The
modest improvement in 6MWD in corrected CHD-PAH patients
in GRIPHON may reflect the large percentage of patients who
were receiving PAH therapy at baseline and who were in WHO
FC II, as well as the prevalent nature of the patients. Reasons
for the difference observed between the 6MWD results in this
analysis and PATENT are unknown, but may depend on patient
variables, such as the length of time since surgical repair, or dif-
ferences in the proportion of CHD patients taking background
therapy (68.2% in GRIPHON vs. 43% in PATENT12). There was no
significant decrease in NT-proBNP levels with selexipag treatment
in patients with corrected CHD-PAH in contrast to the overall
GRIPHON population13 and PATENT.12 This may be because of the
low baseline NT-proBNP levels in GRIPHON, along with the imbal-
ance in baseline NT-proBNP levels observed between the placebo
and selexipag groups.
Using the approach of individualised dosing based on
tolerability, corrected CHD-PAH patients were distributed
relatively evenly amongst the three dose groups. This is consistent ..
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.. with what was observed in the overall study,13 supporting the same
titration approach in both populations. In patients with corrected
CHD-PAH, the tolerability of selexipag was comparable to that of
the overall study population.13 Patients with corrected CHD-PAH
had a longer treatment exposure than the overall population;
contributors to this include a lower proportion of patients exiting
due to both primary endpoint events and AEs in selexipag-treated
corrected CHD-PAH patients.13 The most frequently reported
AEs are suggestive of selexipag’s mode of action as an IP receptor
agonist. There were no new or unexpected safety findings in
corrected CHD-PAH patients, supporting the safety of selexipag
treatment in this population.
This analysis has several strengths in comparison with other
RCTs that included corrected CHD-PAH patients.11,12,14 Firstly,
the study population was larger and this study provided long-term
data. Furthermore, the majority of patients received PAH therapy
at baseline. As PAH patients are now frequently treated with
combination therapy,22 the GRIPHON population reflects patients
in clinical practice.
Investigating the consistency of the selexipag treatment effect
on the primary endpoint across subgroups, including corrected
CHD-PAH patients, was a pre-specified analysis. However, the
additional analyses of selexipag efficacy and tolerability in this
patient group are post-hoc and, therefore, not sufficiently powered
for formal statistical analysis, and are exploratory in nature. Other
limitations are that only patients with simple defects were enrolled
and the lack of data on when patients received corrective surgery.
The exact anatomy of the defect before closure and pre-operative
haemodynamic profile of these patients are also not known as
the study was not designed to collect these data; this limitation
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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is common to all clinical trials that enrol corrected CHD-PAH
patients to date. Although greater than in previous studies, the
number of patients in this analysis is still relatively small, preventing
any subgroup comparison between patients with different types of
defects.
Conclusions
These post-hoc analyses suggest that selexipag may delay dis-
ease progression and is well tolerated in patients with corrected
CHD-PAH. These findings add to the emerging body of evi-
dence that PAH therapies can benefit patients with corrected
CHD-PAH.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. Individual maintenance dose of patients with corrected
CHD-PAH.
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